ProfileGDS5678 / 1425991_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 27% 23% 25% 11% 39% 23% 18% 21% 44% 24% 26% 32% 24% 25% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.6616127
GSM967853U87-EV human glioblastoma xenograft - Control 22.5407923
GSM967854U87-EV human glioblastoma xenograft - Control 32.5795125
GSM967855U87-EV human glioblastoma xenograft - Control 42.2287611
GSM967856U87-EV human glioblastoma xenograft - Control 52.8346939
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.6024423
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.4566618
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.4868721
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.9906944
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.5559724
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.5892426
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.6855332
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.551424
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.5673825